Breaking Finance News

A statement released earlier today by H.C. Wainwright about Capricor Therapeutics (NASDAQ:CAPR) bumps the target price to $6.50

H.C. Wainwright bumped up the target of Capricor Therapeutics (NASDAQ:CAPR) to $6.50 stating a possible upside of 5.57%.

Previously on 7/06/2016, H.C. Wainwright reported on Capricor Therapeutics (NASDAQ:CAPR) increased the target price from $0.00 to $13.00. At the time, this indicated a possible upside of 2.14%.

Yesterday Capricor Therapeutics (NASDAQ:CAPR) traded 6.26% higher at $0.99. The company’s 50-day moving average is $1.07 and its 200-day moving average is $1.74. The last closing price is down -40.78% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 819,167 shares of the stock traded hands, down from an average trading volume of 1,333,410

See Chart Below

Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics has a 52 week low of $0.63 and a 52 week high of $4.00 The company’s market cap is currently $0.

In addition to H.C. Wainwright reporting its stock price target, a total of 1 broker has issued a report on the company. The average stock price target is $12.00 with 0 brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *